Fig. 2: High EDIL3 protein expression is associated with a mesenchymal phenotype in paclitaxel-resistant cancer cells. | Cell Death Discovery

Fig. 2: High EDIL3 protein expression is associated with a mesenchymal phenotype in paclitaxel-resistant cancer cells.

From: EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells

Fig. 2

Western blot analysis of basal expression of EDIL3, and different epithelial and mesenchymal markers are shown. β-actin is shown as a loading control. Histograms show the densitometric analyses of indicated proteins. Data are presented as mean ± SEM (n ≥ 3). a EDIL3 expression in MDA-MB-468, MDA-MB-468R, BT474, SKBR3, and MDA-MB-231 breast cancer cells. b E-cadherin, vimentin, and Slug expression in MDA-MB-468, MDA-MB-468R, and MDA-MB-231 breast cancer cells. c EDIL3, E-cadherin, vimentin, and Slug expression in LNCaP and PC3 prostate cancer cells. d, e Representative micrographs of EDIL3 immunohistochemistry in low- and high-grade breast tumors (d), and in low- and high-grade prostate tumors (e). Bars, 75 µm. Histograms show percent of breast (d) or prostate (e) tumors with high EDIL3 expression. Association between EDIL3 and tumor grade was analyzed by Fisher’s exact test. *P < 0.05 from Student’s t test; NS not significant.

Back to article page